BRAF and colorectal carcinoma: The recent BEACON CRC trial demonstrated that the novel triplet regimen of encorafenib, binimetinib, and cetuximab, and the doublet one of encorafenib and cetuximab had superior efficacy compared to the standard therapy for patients with previously treated unresectable BRAF V600E‐mutant mCRC.17, 21